BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1125 related articles for article (PubMed ID: 20226618)

  • 1. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.
    Mehilli J; Byrne RA; Tiroch K; Pinieck S; Schulz S; Kufner S; Massberg S; Laugwitz KL; Schömig A; Kastrati A;
    J Am Coll Cardiol; 2010 Jun; 55(24):2710-6. PubMed ID: 20226618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.
    Kufner S; Byrne RA; de Waha A; Schulz S; Joner M; Laugwitz KL; Kastrati A;
    Cardiovasc Revasc Med; 2014 Mar; 15(2):69-75. PubMed ID: 24684757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.
    King L; Byrne RA; Mehilli J; Schömig A; Kastrati A; Pache J
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E23-8. PubMed ID: 22431239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents.
    Chevalier B; Moulichon R; Teiger E; Brunel P; Metzger JP; Pansieri M; Carrie D; Stoll HP; Wittebols K; Spaulding C; Fajadet J;
    J Interv Cardiol; 2012 Dec; 25(6):586-95. PubMed ID: 22994863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
    Byrne RA; Kastrati A; Tiroch K; Schulz S; Pache J; Pinieck S; Massberg S; Seyfarth M; Laugwitz KL; Birkmeier KA; Schömig A; Mehilli J;
    J Am Coll Cardiol; 2010 Jun; 55(23):2536-43. PubMed ID: 20417052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
    Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial.
    Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
    Am Heart J; 2009 Oct; 158(4):e43-50. PubMed ID: 19781402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.
    Byrne RA; Kastrati A; Massberg S; Wieczorek A; Laugwitz KL; Hadamitzky M; Schulz S; Pache J; Fusaro M; Hausleiter J; Schömig A; Mehilli J;
    J Am Coll Cardiol; 2011 Sep; 58(13):1325-31. PubMed ID: 21920260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.
    Di Lorenzo E; Sauro R; Varricchio A; Carbone G; Cortese G; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
    Circulation; 2009 Sep; 120(11):964-72. PubMed ID: 19720939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial.
    Maeng M; Jensen LO; Galloe AM; Thayssen P; Christiansen EH; Hansen KN; Helqvist S; Botker HE; Lassen JF; Thuesen L
    Am J Cardiol; 2009 Feb; 103(3):345-9. PubMed ID: 19166687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.
    Chen J; Li JJ; Chen JL; Qiao SB; Xu B; Yang YJ; Gao RL; Qin XW; Yuan JQ; Yao M; Wu YJ; Liu HB; Dai J; You SJ
    Coron Artery Dis; 2008 Nov; 19(7):507-11. PubMed ID: 18923247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients.
    Kim MH; Hong SJ; Cha KS; Park HS; Chae SC; Hur SH; Gwon HC; Bae JH; Lim DS
    J Interv Cardiol; 2008 Jun; 21(3):225-31. PubMed ID: 18341520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymer-free sirolimus-eluting versus polymer-based paclitaxel-eluting stents: an individual patient data analysis of randomized trials.
    Cassese S; Desch S; Kastrati A; Byrne RA; King L; Tada T; Lauer B; Schömig A; Thiele H; Pache J
    Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):435-42. PubMed ID: 24776045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
    Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
    JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-month angiographic and one-year clinical outcomes of polymer free paclitaxel-eluting stent in patients with ST-segment elevation myocardial infarction: a comparison with permanent polymer sirolimus-eluting stent.
    Dang Q; Li YJ; Gao L; Jin Z; Gou LX
    Chin Med J (Engl); 2012 Oct; 125(19):3393-7. PubMed ID: 23044294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis of randomized trials.
    Sethi A; Bahekar A; Bhuriya R; Bajaj A; Singh PP; Arora R; Khosla S
    Arch Cardiovasc Dis; 2012 Nov; 105(11):544-56. PubMed ID: 23177483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease.
    Kim YH; Park SW; Lee SW; Park DW; Yun SC; Lee CW; Hong MK; Kim HS; Ko JK; Park JH; Lee JH; Choi SW; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Park SJ;
    Circulation; 2006 Nov; 114(20):2148-53. PubMed ID: 17060388
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 57.